605369.SHG Zhejiang Gongdong Medical Technology Co Ltd
- Market cap
- CNY 3.89B
- P/E
- 55.3x
- P/B
- 2.14x
- ROE
- 7.1%
- Dividend yield
- 1.69%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 605369.SHG undervalued?
Graham number605369.SHG trades 129.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zhejiang Gongdong Medical Technology Co Ltd fundamental analysis
No fundamental analysis for Zhejiang Gongdong Medical Technology Co Ltd yet.
Zhejiang Gongdong Medical Technology Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zhejiang Gongdong Medical Technology Co Ltd
Zhejiang Gongdong Medical Technology Co., Ltd. researches, develops, produces, and sells disposable medical consumables in China and internationally. Its products include blood collection tubes, needles, and needle holders, as well as sharp containers; cell culture dishes, plates, bottles, and flasks; serological pipette products; laboratory consumables, such as petri dishes, centrifuge and cryo tubes, pipette tips, transfer pipettes, cuvettes, and test tubes; and urine, sto…
Full company profileZhejiang Gongdong Medical Technology Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zhejiang Gongdong Medical Technology Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 371M | 431M | 483M | 553M | 830M | 1.19B | 1.47B | 975M | 1.12B | 1.14B | 1.19B |
| Gross Profit | 151M | 180M | 197M | 245M | 391M | 525M | 575M | 314M | 363M | 317M | 368M |
| Operating Income | 70.6M | 67.1M | 96.6M | 132M | 263M | 360M | 372M | 120M | 192M | 113M | 163M |
| EBITDA | 83.3M | 79.0M | 112M | 149M | 282M | 383M | 411M | 205M | 274M | 169M | 142M |
| Net Income | 60.5M | 54.5M | 85.7M | 114M | 226M | 311M | 326M | 109M | 172M | 51.5M | 123M |
| EPS | 0.37 | 0.33 | 0.52 | 0.69 | 1.27 | 1.41 | 1.48 | 0.49 | 0.78 | 0.23 | 0.56 |
| Balance Sheet | |||||||||||
| Total Assets | 352M | 329M | 464M | 536M | 1.38B | 1.69B | 1.87B | 1.88B | 1.95B | 2.12B | 2.16B |
| Total Liabilities | 164M | 76.2M | 123M | 131M | 168M | 302M | 275M | 239M | 234M | 413M | 412M |
| Shareholders' Equity | 188M | 253M | 341M | 405M | 1.21B | 1.39B | 1.59B | 1.64B | 1.71B | 1.69B | 1.73B |
| Cash & Short-term Investments | 65.2M | 87.6M | 186M | 115M | 814M | 808M | 753M | 448M | 444M | 533M | 570M |
| Total Debt | 55.0M | 10.0M | 40.0M | - | - | 935K | 314K | 31.5M | 38.9M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 86.1M | 85.5M | 102M | 122M | 242M | 373M | 283M | 185M | 210M | 254M | - |
| Capital Expenditure | 11.0M | 12.5M | 35.9M | 102M | 109M | 276M | 172M | 122M | 110M | 112M | 124M |
| Free Cash Flow | 75.1M | 73.0M | 66.6M | 20.0M | 134M | 97.4M | 111M | 63.6M | 101M | 142M | 169M |
| Ratios | |||||||||||
| ROE | 32.2% | 21.6% | 25.1% | 28.0% | 18.7% | 22.4% | 20.5% | 6.7% | 10.1% | 3.1% | 7.1% |
| ROA | 17.2% | 16.6% | 18.5% | 21.2% | 16.4% | 18.4% | 17.5% | 5.8% | 8.8% | 2.4% | 5.7% |
| Net Profit Margin | 16.3% | 12.6% | 17.8% | 20.5% | 27.2% | 26.0% | 22.2% | 11.2% | 15.4% | 4.5% | 10.3% |
| Debt to Equity | 0.29x | 0.04x | 0.12x | - | - | 0.00x | 0.00x | 0.02x | 0.02x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Zhejiang Gongdong Medical Technology Co Ltd dividends
- Dividend yield
- 1.69%
- Forward dividend
- 0.15 CNY
- Payout ratio
- 127.5%
- Ex-dividend date
- Jun 18, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 65.7M | 0.30 | 127.5% |
| 2024 | CNY 81.2M | 0.37 | 47.3% |
| 2023 | CNY 90.1M | 0.41 | 82.6% |
| 2022 | CNY 155M | 0.71 | 47.7% |
| 2021 | CNY 144M | 0.65 | 46.3% |
| 2020 | - | - | - |
| 2019 | CNY 50.7M | 0.31 | 44.6% |
| 2018 | 255K | 0.00 | 0.3% |
| 2017 | 66.4M | 0.40 | 121.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Jun 26, 2025.
Who owns Zhejiang Gongdong Medical Technology Co Ltd
- Insiders 68.93%
- Institutions 5.28%
- Public & others 25.79%
- Shares outstanding 220M
- Free float 65.5M
Zhejiang Gongdong Medical Technology Co Ltd company profile
- Company name
- Zhejiang Gongdong Medical Technology Co Ltd
- Ticker
- 605369.SHG
- ISIN
- CNE1000042X4
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 1,659
- Fiscal year end
- December
- Address
- No. 10, Beiyuan Avenue, Taizhou, China, 318020
- Phone
- 86 576 8411 5678
- Website
- gongdong.com
About Zhejiang Gongdong Medical Technology Co Ltd
Zhejiang Gongdong Medical Technology Co., Ltd. researches, develops, produces, and sells disposable medical consumables in China and internationally. Its products include blood collection tubes, needles, and needle holders, as well as sharp containers; cell culture dishes, plates, bottles, and flasks; serological pipette products; laboratory consumables, such as petri dishes, centrifuge and cryo tubes, pipette tips, transfer pipettes, cuvettes, and test tubes; and urine, stool, and sputum specimen collection containers. The company also offers vaginal, ear, and anus speculum products, as well as sponge forceps nursing plasticwares; and customized solutions, including bespoke plastic medical products. Zhejiang Gongdong Medical Technology Co., Ltd. was founded in 1985 and is based in Taizhou, China.
Zhejiang Gongdong Medical Technology Co Ltd management
4- Mr. Weifeng ZhongGM & Director · born 1977
- Mr. Yong ZhuDeputy GM & CFO · born 1979
- Mr. Shangxiao LaiDeputy General Manager · born 1978
- Ms. Ling Ting MuSecretary · born 1990